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IFNL3 mRNA structure is 
remodeled by a functional non-
coding polymorphism associated 
with hepatitis C virus clearance
Yi-Fan Lu1,3,*, David M. Mauger2,*, David B. Goldstein3, Thomas J. Urban4, Kevin M. Weeks2 
& Shelton S. Bradrick1,5
Polymorphisms near the interferon lambda 3 (IFNL3) gene strongly predict clearance of hepatitis 
C virus (HCV) infection. We analyzed a variant (rs4803217 G/T) located within the IFNL3 mRNA 3′ 
untranslated region (UTR); the G allele (protective allele) is associated with elevated therapeutic 
HCV clearance. We show that the IFNL3 3′ UTR represses mRNA translation and the rs4803217 
allele modulates the extent of translational regulation. We analyzed the structures of IFNL3 variant 
mRNAs at nucleotide resolution by SHAPE-MaP. The rs4803217 G allele mRNA forms well-defined 3′ 
UTR structure while the T allele mRNA is more dynamic. The observed differences between alleles 
are among the largest possible RNA structural alterations that can be induced by a single nucleotide 
change and transform the UTR from a single well-defined conformation to one with multiple dynamic 
interconverting structures. These data illustrate that non-coding genetic variants can have significant 
functional effects by impacting RNA structure.
Human genetic variation has a large influence on an individual’s susceptibility to infectious diseases. 
Studies on the hepatitis C virus (HCV), a major cause of liver disease1, have revealed a striking example 
of how human genetics affects the outcome of infection. Genome-wide association studies performed 
on diverse patient populations have identified polymorphisms near the interferon-λ 3 (IFNL3; formerly 
IL28B) gene that predict the efficacy of interferon-based therapy for chronic infection. These polymor-
phisms are also strongly predictive of spontaneous HCV clearance during the acute phase of infection2–5.
IFNL3 is a secreted cytokine that binds a specific cell surface receptor complex expressed on epithelial 
cells, leading to JAK-STAT signal transduction and expression of interferon-stimulated genes6–8. IFNLs 
have been implicated in control of viral infections of epithelial-derived tissues, such as gut, lung, and 
liver9–12. IFNLs inhibit replication of multiple viruses in vitro13–15 and IFNL3 genotype has been linked 
to liver interferon-stimulated gene mRNA expression in chronic HCV patients and primary human 
hepatocytes16–18.
The mechanisms by which IFNL3 genetic variants function to control HCV infection are not clear. 
Steady-state levels of IFNL3 mRNA in liver tissue and peripheral blood mononuclear cells may be linked 
to HCV clearance because the protective alleles (rs12979860 C and rs8099917 T) are correlated with a 
modest (< 2-fold) increase in IFNL3 mRNA levels3,4,19,20. However, other studies on different patient 
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populations and cell types failed to detect correlations between differences in IFNL3 mRNA expression 
and genotype in liver tissue16,17 or plasmacytoid dendritic cells21. Thus, the propensity for HCV clearance 
appears to be related to differences beyond IFNL3 mRNA levels.
Although primary hepatocyte cultures have been shown to express IFNL3 upon HCV infection9,22, 
evidence is emerging to support a role for dendritic cell subtypes in the production of IFNL323–25. In 
addition, levels of IFNL3 protein were found to be strongly correlated with IFNL3 genotype in serum 
samples from HCV-infected patients26,27. One study also suggested that serum IFNL3 levels are a stronger 
predictor of viral clearance than IFNL3 genotype28. These observations, taken together, suggest that 
IFNL3 abundance may be regulated by differential efficiency of mRNA translation as a function of IFNL3 
genotype.
Here we report the genetic association and functional consequences of a SNP (rs4803217) located in 
the 3′ untranslated region (UTR) of IFNL3 mRNA. This SNP was previously reported to regulate IFNL3 
expression by changing seed base pairing with HCV-induced microRNAs29. We genotyped a large num-
ber of patients with chronic hepatitis C from the IDEAL Cohort30 to evaluate associations of this variant 
with treatment phenotypes. Molecular analyses suggested that rs4803217 is functional in regulation of 
mRNA translation efficiency. RNA structure probing by SHAPE provided a physical explanation for these 
functional differences and revealed that IFNL3 mRNA structure is markedly altered by this common 
SNP. Together, these findings support a model in which IFNL3 mRNA translation efficiency, governed 
by allele-specific mRNA structures, modulates clearance of HCV infection.
Results
The rs12979860 discovery SNP and rs4803217 are highly correlated and exhibit indistin-
guishable associations with clinical phenotypes. The most strongly associated single nucle-
otide polymorphisms (SNPs) found in genome-wide association studies (GWAS) were rs12979860 in 
European-Americans and African-Americans, and rs8099917 in East Asians. These SNPs likely co-seg-
regate with polymorphisms that directly affect biological functions related to IFNL expression or activity. 
To identify candidate functional variants in the IFNL3 gene region, we searched for variants in high link-
age disequilibrium with rs12979860 (hereafter referred to as the ‘discovery SNP’) by analysis of available 
human genome sequence data (1000genomes.org). We identified a SNP (rs4803217) in the 3′ UTR of 
IFNL3 that is highly correlated (best tagging SNP according to 1000 Genomes Project) to the discovery 
SNP31–34 (Fig. 1A). The rs4803217 G allele is correlated with the protective C allele of the discovery SNP. 
This variant was an intriguing candidate as the source of viral infection-related phenotypes because 3′ 
UTRs often contain cis-acting RNA elements that control mRNA translation and decay. Rs4803217 is 
also flanked by AU-rich elements (AREs; Fig. 1B), sequence motifs that have been linked to post-tran-
scriptional gene regulation35. Therefore, we conducted a large-scale genetic association study examining 
rs4803217 and HCV clearance in a cohort of chronically-infected patients.
We genotyped and analyzed these variants in the IDEAL Cohort30, a large sample of chronic HCV 
patients treated with pegylated IFN-α and ribavirin combination therapy (n = 792 European-American; 
n = 169 African-American). The sample sizes of both populations are sufficient to achieve greater than 
0.99 in statistical power (1.00 in European-American and 0.992 in African-American under the signifi-
cance level of 0.01). Linkage disequilibrium analysis in HCV patients revealed that rs4803217 is strongly 
associated with rs12979860 in European-American patients (r2 > 0.97; Table  1), with somewhat lower 
linkage disequilibrium in African-Americans (r2 = 0.913). We performed association tests of rs4803217 
with clinical phenotypes using logistic regression. The association of rs4803217 with sustained virolog-
ical response (defined as absence of detectable HCV RNA in serum at least 24 weeks after discontinu-
ation of treatment) was extremely significant (p = 2.48 × 10−25) in the European-American population 
(Table 1). The discovery SNP has been previously associated with viral burden such that patients with 
the protective allele (C) exhibit a slightly higher baseline viral load2. We found that rs4803217 exhibited 
comparable association with pre-treatment baseline viral load by linear regression in both European- and 
African-Americans compared with the discovery SNP (Table 2).
Next, we performed a multiple logistic regression analysis to examine whether rs4803217 showed 
independent association with patient phenotypes in excess of that attributed to the discovery SNP. This 
analysis revealed that rs4803217 did not show significant association with SVR when we adjusted for 
rs12979860 genotype, in either European- or African-Americans (Table  1). Thus, although the IDEAL 
cohort is one of the largest and most data-rich clinical trial cohorts available for genetic studies of patient 
response to IFN-based therapy, the extremely high linkage disequilibrium between variants in this region 
precluded independent statistical association of rs4803217 with SVR in this sample size.
Recently, a functional dinucleotide SNP rs368234815 that can influence the expression of IFNL4 pro-
tein was discovered upstream of the IFNL3 locus and was implicated in the clearance of HCV36. In addi-
tion, the putatively favorable rs4803217 G allele was proposed to have an unexpected negative effect on the 
decrease of HCV RNA level after treatment in the presence of the unfavorable rs368234815 Δ G allele37, 
suggesting that rs4803217 may modify the effect of the rs368234815 variant associated with IFNL4. Here, 
we also performed the same multiple logistic regression or multiple linear regression approaches to assess 
whether rs4803217 or rs368234815 showed stronger association with patient phenotypes. We found that, 
despite the large sample size of the IDEAL cohort, this analysis did not reveal significant independent 
association of either SNP after correcting for the effect of each other (Table 1 and Table 2), although we 
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note an interesting opposite trend of odds ratios (OR) for SVR after mutual adjustment (0.78 and 2.64 
for rs4803217 G and rs368234815 TT, respectively) in African American patients (Table 1).
Overall, rs4803217 demonstrated similar levels of association with patient phenotypes as did the 
discovery SNP or a nearby functional SNP rs368234815, suggesting that rs4803217 is an interesting 
candidate variant and may be responsible for clinically important phenotypic differences.
rs4803217 impacts IFNL3 mRNA translation efficiency. Although rs4803217 did not inde-
pendently predict SVR in patients, based on association evidence it is a good candidate to investigate. 
Furthermore, its presence in the IFNL3 mRNA 3′ UTR prompted us to test functionality. The IFNL3 
3′ UTR is 176 nucleotides (nt) in length, is composed of 65% A and U nucleotides, and harbors several 
functional AREs29, including two (ARE1 and ARE2) flanking rs4803217 (Fig. 1B). Comparison of UTRs 
from primate IFNL3 and IFNL2 genes indicates that the region around rs4803217 is highly conserved 
and that the T variant is the ancestral allele (Supplementary Figure S1).
We first evaluated the effects of the variant IFNL3 3′ UTRs on steady-state mRNA and protein levels 
using a reporter assay. We took advantage of a stable HeLa cell line that harbors a genomic flippase recog-
nition target site38 to create isogenic cell lines with distinct Renilla luciferase (RLuc) reporter constructs 
controlled by a CMV promoter that is transcriptionally regulated by tetracycline repressor protein. This 
system allows characterization of gene expression in cells containing a single copy of the reporter gene. 
Three cell lines were established containing either RLuc alone or RLuc fused to each of the two IFNL3 3′ 
UTR variants (Fig. 1C). The presence of either IFNL3 3′ UTR caused modest but statistically significant 
(p = 0.028 for G allele, p = 0.046 for T allele, unpaired t-test) reductions in the levels of IFNL3 chimeric 
mRNAs compared to RLuc alone (Fig.  1D). Interestingly, levels of the RLuc protein were reduced by 
a much larger amount, 4- and 7-fold for the rs4803217 G and T reporters, respectively, compared to 
Figure 1. Variant IFNL3 3′ UTRs differentially inhibit reporter gene expression. (A) IFNL genes and 
genetic variants. (B) The IFNL3 mRNA 3′ UTR sequence. The three AREs (1–3) are indicated in red and 
the rs4803217 SNP is bracketed. (C) IFNL3 reporter constructs. Transcription of each reporter mRNA 
is directed by the constitutive CMV promoter. (D) Relative levels of each RLuc reporter mRNA. RNA 
levels were normalized to GAPDH; asterisk indicates that differences are significant at the p < 0.05 level. 
(E) RLuc protein levels. Protein levels were measured by luciferase assay and normalized to total protein. 
Triple asterisks indicate that differences are significant at the p < 0.001 level. All data are shown as mean 
values ± s.d.
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the reporter lacking an IFNL3 3’ UTR (Fig.  1E). The differential effects on mRNA versus protein lev-
els strongly suggest that the IFNL3 3′ UTR regulates gene expression by repressing the efficiency of 
mRNA translation rather than mRNA abundance in HeLa cells. Importantly, the 3′ UTR SNP affected 
the magnitude of this repression: the rs4803217 T allele produced approximately 50% less RLuc than did 
the corresponding G allele mRNA (Fig.  1E; p = 0.0005, unpaired t-test). Induction of reporter mRNA 
expression levels by tetracycline treatment reduced RLuc differences between the cell lines, suggesting 
that reporter mRNA over-expression led to escape from endogenous regulatory factor(s) present in HeLa 
cells (Supplementary Figure S2A,B). We also tested the IFNL3 reporter constructs in an immortalized 
human hepatocyte cell line (PH5CH8), a human hepatoma cell line (LH86), and HeLa cells by transient 
plasmid transfection (Supplementary Figure S2C). In each cell line, the patterns of reporter expression 
mirrored that in the stable HeLa cell lines (Fig. 1E).
We next directly tested the hypothesis that rs4803217 regulated efficiency of mRNA translation. We 
used polysome profiling to examine whether the variant IFNL3 reporter mRNAs were differentially 
associated with translating ribosomes in stable HeLa cell lines. The extent of association with multiple 
ribosomes is an indication of mRNA translation efficiency. IFNL3 variant reporter cell lines, grown to 
equal densities, were harvested, lysed and subjected to sucrose density gradient centrifugation to sep-
arate non-translating and ribosome-associated mRNA. Gradients were subsequently fractionated and 










Discovery SNP in GWAS
rs12979860-C - 3.92 4.18 × 10−25 - - 2.10 0.006 -
Candidate functional variant
rs4803217-G 0.977 3.93 2.48 × 10−25 0.219 0.913 1.77 0.030 0.100
rs368234815-TT 0.977 3.96 1.81 × 10−25 0.118 0.708 2.13 0.004 0.328
European-American N = 792 African-American N = 169










rs4803217-G (correcting for 
rs368234815-TT) 0.965 1.69 0.393 0.701 0.78 0.629
rs368234815-TT (correcting for 
rs4803217-G) 2.37 0.158 2.64 0.065
Table 1.  Association of rs4803217 with SVR in the IDEAL cohort. Logistic regression or multiple logistic 
regression were performed by additive genetic model. *r2 represents pairwise LD with GWAS discovery SNP 








Discovery SNP in GWAS
rs12979860-C 12.89 7.81 × 10−7 - 20.68 5.41 × 10−6 -
Candidate functional variant
rs4803217-G 12.61 1.35 × 10−6 0.793 21.25 2.25 × 10−6 0.196
rs368234815-TT 13.03 5.77 × 10−7 0.412 22.20 7.57 × 10−7 0.037
European-American N = 792 African-American N = 169
Comparison between functional 
SNPs coefficient P coefficient P
rs4803217-G (correcting for 
rs368234815-TT) -5.79 0.677 9.04 0.253
rs368234815-TT (correcting for 
rs4803217-G) 18.71 0.178 14.61 0.066
Table 2.  Association of rs4803217 with the pre-treatment viral load. Association tests were performed by 
linear regression or multiple linear regression (additive genetic model).
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patterns from the IFNL3 two reporter cell lines were nearly identical (Fig.  2A), indicating that bulk 
mRNA translation rates did not differ between cell lines. In contrast, the rs4803217 G and T IFNL3 
reporter mRNAs showed distinct profiles across the gradient. Across three biological replicates, the G 
allele mRNA was more highly represented in denser gradient fractions, reflecting incorporation into 
polysomes, than the T allele mRNA (Fig. 2B,C and Supplementary Figure S3). We quantified the areas 
underneath the lines for both G and T alleles and found that the allelic difference in area between pol-
ysome fractions (fractions 7–12) and non-polysome (fractions 1–6) fractions were significantly different 
(p = 0.01) (Fig. 2C). This result indicates that the G allele mRNA was more abundant in polysome frac-
tions compared to the T allele mRNA. Correspondingly, levels of non-translating mRNA (sedimenting 
between the 40S ribosomal subunit and the 80S monosome) were higher for the rs4803217 T mRNA. 
Figure 2. Polysome profiles of IFNL3 reporter mRNAs. (A) Top: Representative ribosome profiles. 
Locations of the 40S subunit, 80S monosome, and polysome peaks are indicated. Profiles were obtained 
using a sucrose density gradient, monitored by absorbance trace (254 nm). Bottom: Analysis of extracted 
total RNA samples in each gradient fraction for each IFNL3 reporter cell line. Ribosomal RNA species 
are indicated at right. (B) Relative levels of RLuc reporter mRNA normalized to GAPDH mRNA for each 
IFNL3 cell line as a function of ribosome gradient fraction. The relative levels (%) of each mRNA in each 
gradient fraction are indicated. (C) Areas underneath the lines in Figures 2B and S3 were quantified for 
both polysome fractions (fractions 7–12) and non-polysome fractions (fractions 1–6). The plot shows 
the differences in area between the G and T alleles (G minus T). Unpaired t-test (two-tailed) was used to 
calculate the P value from the three independent experiments (p = 0.01). Error bar represents the SEM.
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We did note that a significant amount (15%) of the T-allele reporter mRNA was found in dense gradient 
fractions (10–12), suggesting that a portion of the T allele reporter mRNA escapes repression and is effi-
ciently translated. Combined with the discrepant luciferase protein and reporter mRNA measurements 
shown in Fig. 1, these data strongly suggest that the rs4803217 SNP regulates efficiency of IFNL3 reporter 
mRNA translation in HeLa cells.
rs4803217 alters structural conformation of the IFNL3 3′ UTR. There is extensive literature 
linking 3′ UTRs with translational control [see reference39 for a recent review]. A growing body of 
evidence indicates that 3′ UTR structure regulates mRNA translation and decay by modulating inter-
actions with trans-acting factors40. Moreover, genetic variants that alter mRNA structure and function, 
termed RiboSNitches, have been described41. We directly examined whether the rs4803217 SNP physi-
cally modulates the structure of endogenously expressed IFNL3 mRNA using selective 2′-hydroxyl acy-
lation analyzed by primer extension (SHAPE)42. We examined the structure of IFNL3 mRNA under 
non-denaturing conditions in the context of total purified cellular RNA. SHAPE analysis was performed 
on deproteinized RNA as this approach allows for direct assessment of mRNA structure independently 
of trans-acting proteins or RNAs. The structure of the IFNL3 mRNA was probed using the fast-reacting 
SHAPE reagent 1-methyl-7-nitroisatoic anhydride (1M7) and products were analyzed by massively par-
allel sequencing using the SHAPE-MaP strategy43 (Supplementary Figure S4). We used human A549 
lung adenocarcinoma cells for these experiments because they express IFNL3 mRNA upon transfection 
with poly(I:C) (Supplementary Figure S5A). Importantly, A549 cells are heterozygous at rs4803217 and 
levels of mRNA from each allele were directly correlated with the gene dosage (Supplementary Figure 
S5B). Using the MaP approach, sequencing reads derived from IFNL3 were sorted by SNP identity at 
rs4803217; this made it possible to examine the structures of both alleles under identical conditions in 
the same experiment (Supplementary Figure S4). SHAPE data were collected on a 266 nt long region of 
the IFNL3 mRNA containing the last 125 nt of the coding sequence (including the stop codon) and the 
3′ UTR, excluding the terminal 23 nt and the poly(A) tail.
SHAPE-MaP reactivities report a model-free measurement of the degree of RNA structure42,43. The 
rs4803217 G allele had lower SHAPE reactivity, and thus more stable structure, near the region close to 
rs4803217 than did the T allele (Fig. 3A). We next calculated Shannon entropy values for each rs4803217 
allele. Shannon entropies are derived from a SHAPE-directed partition function and report a measure 
of whether an RNA region is likely to form a single well-defined structure43–45. The median Shannon 
entropies across the IFNL3′ UTR were much lower for the G allele, especially near the rs4803217 site, 
than for the T variant (Fig. 3B and Supplementary Figure S6). We next performed a correlation analysis 
of SHAPE reactivities between the G and T alleles by calculating R2 across the mRNA regions to address 
the overall structural similarity between the two alleles (Fig.  3C). The SHAPE reactivities in the open 
reading frame (ORF) are highly correlated between alleles, and moderately correlated at the very end of 
3′ UTR. In contrast, a very low or zero correlation was observed in the region of rs4803217. This indi-
cates that a drastic local change in structure is induced by the SNP. In sum, the G allele 3′ UTR adopts 
an overall well-defined, highly structured conformation; whereas, nucleotide-resolution SHAPE probing 
indicates that the T allele adopts multiple conformations. In addition, structural differences between the 
two 3′ UTR alleles are centered on the SNP region.
SHAPE data can be used to develop accurate models for large, complexly structured RNAs with 
well-defined structures46,47. SHAPE-directed RNA structure models for each variant over the 3′ portion 
of the open reading frame and 3′ UTR are summarized in arc plots that display predicted short- and 
long-range base pairing (Fig. 3D). Given its low Shannon entropy, the structure of the G allele could be 
modeled with a high degree of confidence, as evidenced by the preponderance of highly probable helices 
(Fig. 3D, bottom). In contrast, the 3′ UTR for the T allele is predicted to adopt multiple conformations, 
comprised of helices with base pairs of lower individual probability (Fig. 3D, top). The combined SHAPE 
reactivity and entropy differences indicate that the T-allele mRNA has a more variable structure than 
the G-allele mRNA.
The SHAPE-directed RNA secondary structure model indicated that the rs4803217 G nucleotide forms 
a canonical base pair within a stable stem-loop (Fig. 4A and Supplementary Figure S7) that contains por-
tions of ARE1 and ARE2. In contrast, the U variant is not predicted to stably adopt this stem-loop struc-
ture (Fig. 4A). We calculated the free energy change of 3′ UTR RNA folding48 for each allele and found 
that the rs4803217 G to U change alters relative free energy by approximately 7 kcal/mol. This difference 
in relative free energy is close to the largest possible increment achievable by altering a single base pair49. 
We calculated the expected free energy changes for all possible nucleotide changes in the context of the 
IFNL3 3′ UTR (529 sequence variants) and in the context of the intact mRNA (2851 sequence variants). 
The increase in folding free energy due to the change from G to U at rs4803217 ranked the highest 
among all possible substitutions in 3′ UTR, and the third among all possible substitutions in the intact 
mRNA, indicating that this position has a strong influence on RNA folding (Fig.  4B). Direct SHAPE 
experimental interrogation and free energy increment calculations thus suggest that the rs4803217 SNP 
induces close to the largest possible change in RNA structure.
We performed mutagenesis to further test whether functional differences for rs4803217 reflect 
changes in RNA structure. Three mutant versions of the IFNL3 reporter construct were established that 
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contained mutations at the rs4803217 position (nt 52 of the 3′ UTR) and/or at the nt position predicted 
to base-pair with rs4803217 (nt 45 of the 3′ UTR) (Fig. 5A). Changing rs4803217 from G to C resulted 
in reduced expression, similar to the rs4803217 T reporter construct (Fig. 5B). Restoring the predicted 
base pair in this mutant by introducing a G at nt 45 increased expression, consistent with RNA struc-
ture opposing repression. Interestingly, introduction of G at nt 45 (C45G) in the context rs4803217 G, 
which is predicted to interrupt base-pairing, had increased expression which was opposite of the effect 
on expression initially expected. However, this mutant resulted in a free energy of RNA folding similar 
to the rs4803217 G 3′ UTR (Fig. 5B) by inducing a register shift in base pairing and ultimately preserved 
the stem loop associated with escape from repression48 (Supplementary Figure S8). For each of the con-
structs analyzed, the expression levels were inversely correlated with folding free energy. Together, the 
mutagenesis data further reinforce the model that the T-allele has a more variable structure than the 
G-allele mRNA and that stable structure is associated with enhanced HCV clearance.
Figure 3. SNP-induced structural changes in the IFNL3 3′ UTR. (A) SHAPE reactivity profiles. Low 
median SHAPE reactivities correspond to highly structured regions in the RNA. Reactivities are shown as 
the median over 5-nt windows. “Nucleotide position” values indicate nt locations in the context of the total 
SHAPE data (B) Shannon entropies (medians over 5-nt windows). Peaks indicate regions with high Shannon 
entropies and that likely adopt multiple conformations. (C) Correlation of median SHAPE reactivities 
between the G and T alleles. R2 was calculated over 100-nt windows. (D) SHAPE-directed RNA secondary 
structure models for the 3′ UTR. Base pairs are shown as arcs. Arcs are colored by pairing probability.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:16037 | DOi: 10.1038/srep16037
Discussion
Multiple genome-wide association studies have identified polymorphisms near the IFNL3 gene that pre-
dict efficacy of therapy and spontaneous HCV clearance2–5. Although rs4803217 is not independently 
associated with patient phenotypes in the cohort we analyzed, this SNP occurs in the 3′ UTR of IFNL3 
and showed clear functional effects on reporter gene expression, suggesting a role for this variant in 
control of HCV infection.
Rs4803217 influences regulation of mRNA translation efficiency by the IFNL3 3′ UTR in HeLa cells, 
perhaps through altering functionality of AREs. Although cytokine 3′ UTR AREs are commonly asso-
ciated with enhanced mRNA decay, they have also been implicated as translational regulators50–53 and 
mRNA decay and translation are closely associated cytoplasmic processes54,55. Due to gene regulation at 
the level of mRNA translation, the modest differences in IFNL3 mRNA levels, as a function of genotype, 
reported in some studies may underestimate actual differences in IFNL3 protein levels, as we observed 
here for the IFNL3 rs4803217 SNP (Fig. 1). This is consistent with a recent report of ~ 7-fold differences 
in IFNL2/3 serum levels between HCV patients who are homozygous at the discovery SNP26. Consistent 
with this work, a recent independent study identified a distinction between CC versus non-CC genotype 
(discovery SNP) for IFNL3 protein plasma levels27. However, we acknowledge that our results do not 
formally establish a causal relationship between rs4803217 and IFNL3 levels in patients.
To examine and define the physical basis for the mechanism of IFNL3 translational regulation, we 
used the SHAPE-MaP strategy, which made it possible to resolve structural conformations and differ-
ences for the rs4803217 G and U variant mRNAs in a single heterozygous cell line, in a single experi-
ment. We discovered that the nucleotide at rs4803217 influenced the global structure of IFNL3 mRNA. 
The G allele was much more highly structured and the free energy difference between the G- and 
U-containing mRNAs was predicted to be close to the upper limit in structural stabilities achievable by 
a single-nucleotide sequence change.
Our work strongly suggests that rs4803217 is a RiboSNitch41 that alters gene expression by inducing 
changes in RNA structure. Recent genome-wide analyses suggest that RiboSNitches are widespread in the 
Figure 4. Secondary structure models for the IFNL3 3′ UTR. (A) SHAPE-directed RNA secondary 
structure models of the IFNL3 3′ UTR G (top) and T (bottom) alleles. rs4803217 site is shown for each 
structure. Nucleotides are colored by SHAPE reactivity. Highly probable (> 80%) helices for each allele are 
shown. Locations of AU-rich elements are indicated on each allele structure. (B) Calculated free energy 
change increments (Δ Δ G) for all possible nucleotides changes in the IFNL3 3′ UTR (left) or complete 
intact mRNA (right). Batch calculation was performed by mfold 3.0.
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human transcriptome56. The experimental and computational strategies developed here can be applied 
to other candidate functional variants to advance our understanding of how post-transcriptional gene 
regulation is affected by non-coding genetic polymorphisms. These approaches should be broadly useful 
for identifying human genome sequence variants in non-coding regions that exert functional effects by 
altering RNA structure.
The observed change in protein expression is likely the result of differential binding of trans-acting 
factors, induced by the differential folding of the 3′ UTR variants. The SHAPE-derived secondary struc-
tures show that rs4803217 T reduces structure of a region overlapping ARE1 and 2 (Fig. 4A), suggesting 
that unidentified trans-acting ARE-binding proteins may access these elements more efficiently in the 
T allele mRNA. Recently, McFarland et al. reported that the IFNL3 mRNA is regulated by AU-rich ele-
ments and also targeted by muscle-specific micro(mi)RNAs (miR-208b and miR-499a-5p) whose expres-
sion is triggered by HCV replication. These authors found that rs4803217 was functional using IFNL3 
reporter mRNAs. However, the SNP did not confer regulation when ARE1 or ARE2 were mutated, in 
agreement with our observation that rs4803217 alters structural conformation of regions encompass-
ing ARE1 and ARE2. With respect to the mechanism involving action of miRNAs, the rs4803217 T 
to G allele would disrupt miRNA-mRNA seed base-pairing29. Thus, the dramatic effects of rs4803217 
on IFNL3 mRNA structure that we report here may regulate interactions with ARE-binding proteins 
and miRNAs. However, we note that, when the SNP position was mutated to a C, we observed a level 
of reporter expression similar to that of the T-allele (Fig.  5B). The rs4803217 C mutation abolishes 
seed-region base-pairing to the proposed regulatory miRNAs, similar to the G-allele. This suggests that 
the regulation we characterized in HeLa cells, which may lack expression of the implicated miRNAs, is 
mediated primarily by effects of RNA structure on interaction with trans-acting factor(s) other than miR-
208b or miR-499a-5P. Further study is needed to define the complement of relevant trans-acting factors 
that may differentially regulate variant IFNL3 mRNA transcripts through repression of translation and/
or induction of mRNA decay.
Figure 5. Site-directed mutagenesis of the IFNL3 3′ UTR. (A) The rs4803217 G and T allele reporter 
constructs were compared to three mutants in stable HeLa cell lines. (B) Normalized relative light units 
(RLU) for each reporter construct is shown above. Data are shown as mean values ± s.d. and folding free 
energies for the full 3′ UTR sequence are shown.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:16037 | DOi: 10.1038/srep16037
Recently, RNA sequencing analysis of primary human hepatocytes (PHH) revealed transcriptional 
activity upstream of the IFNL3 gene that is coincidentally induced by treatment with poly I:C36. Moreover, 
a dinucleotide variant (rs368234815 TT/Δ G) in this region is associated with HCV clearance and may 
alter translation of a specific mRNA isoform encoding the novel IFNL436. IFNL4 is antiviral against 
HCV in vitro yet is poorly secreted and does not appear to be strongly expressed in PHHs15,57. In the 
rs368234815 Δ G genotype, which is predicted to express IFNL4 and is in high linkage disequilibrium 
(LD) with the non-protective (T) rs12979860 allele, IFNL4 production may exert effects that would be 
unexpectedly deleterious to HCV clearance36. Rs368234815 was recently reported to be more strongly 
associated with some patient phenotypes than rs4803217 in different patient cohorts, and thus may be 
dominant in determining HCV clearance in patients37. Further study is needed to understand the poten-
tially maladaptive effects of IFNL4 expression and dissect possible interactions between rs4803217 and 
ss469415590 variants in control of HCV infection.
In summary, we demonstrate a general strategy involving genetics, molecular biology, and RNA 
chemistry for understanding GWAS associations with non-coding genetic variants that may alter RNA 
structure and post-transcriptional gene regulation. Nucleotide-resolution SHAPE probing revealed that 
the 3′ UTR of the rs4803217 G allele IFNL3 mRNA, which is associated with HCV clearance, forms a 
well-defined structure whereas that of the T allele mRNA is dynamic. The large alteration induced by a 
single nucleotide change illustrates the extent to which non-coding genetic variants can have significant 
functional effects by impacting RNA structure.
Methods
Genotyping and statistical analysis. DNA from the IDEAL cohort was used for genotyping. The 
genotyping of rs4803217 was performed by quantitative PCR (Bioline) using, forward primer 5′-ACCTG 
AGATT TTATT TATAA ATTAG CCACT TG(G/T)-3′, and reverse primer 5′-CTTTT CCTCA TTGTT 
TATTT CAACA AGGAT TTC-3′. Data were clustered by Ct value for genotype calling. Rs368234815 
was genotyped by the TaqMan genotyping assay (Life Technologies) according to the protocol recom-
mended by the manufacturer, forward primer 5′-TGGGT CCTGT GCACG GTGAT-3′, reverse primer 
5′-TCCCT CAGCG CCTTG GCA-3′, and probe 5′-CGCAG (AA/C)GGCC CCCCG G-3′ 15. Statistical 
analysis of phenotypic data was performed in STATA (StataCorp) and R (www.r-project.org). Sustained 
virological response (SVR) was used as the binary dependent variable, and genetic polymorphisms were 
considered independent variables in the logistic regression model (the assumption of logistic regres-
sion requires the dependent variable to be binary). Both discovery SNP and rs4803217 were used as 
independent variables in multiple logistic regression to distinguish its independent association after 
accounting for the effect of each other. Viral loads (IU/ml) were transformed by Box-Cox method and 
considered as the dependent variable in linear regression to meet the multivariate normality assumption. 
Sample size calculation was performed by the pwr package in R and the significance level was set at 
p = 0.01 under the multiple regression setting. All the p values reported in this paper are based on the 
two-sided statistical tests.
Cell culture, cloning and RT-qPCR. PH5CH858, LH8659, A549 and stable HeLa-FRT cells express-
ing TetR were cultured in high glucose DMEM supplemented with 10% heat-inactivated FBS and 
non-essential amino acids. Stable HeLa-FRT cells (a gift from Elena Dobrikova, Duke University) har-
boring RLuc reporter trans-genes were established as described38 by co-transfection of a flp recombinase 
plasmid (pOG44, Life Technologies) with RLUC reporter plasmids cloned into pcDNA5/FRT/TO (Life 
Technologies, see below). Stable cell lines were selected with blasticidin (2.5 μ g/ml) and hygromycin 
(200 μ g/ml). Analysis of RLuc levels (Renilla Luciferase Assay System, Promega) in HeLa cell lines was 
conducted in the absence or presence of tetracycline (1 μ g/ml) induction. Stable reporter cell lines were 
independently derived and analyzed three times. Reporter constructs were generated by PCR amplifi-
cation of the RLuc open reading frame using 5′–GAGGT ACCAT GACTT CGAAA GTTTA TGATC 
C-3′ and 5′–GAGAT ATCTT ATTGT TCATT TTTGA GAACT CGC-3′ and ligation into pcDNA5/
FRT/TO (Life Technologies) using KpnI and EcoRV. The resulting clone was used for insertion of 
IFNL3 3′ UTR sequences PCR amplified from A549 genomic DNA using EcoRV and NotI (primers: 
5′-GAGAT ATCCC CTTCC GCCAG TCATG CAACC TGAG-3′ and 5′-GAGCG GCCGC CGCAC 
ACACA GTCCC ACGTC ATGGG T-3′ ). Mutant constructs were established by cloning custom syn-
thesized DNA fragments (Integrated DNA Technologies). All clones were verified by Sanger sequencing. 
For RT-qPCR, total RNA samples were obtained by RNeasy column purification using on-column DNase 
treatment (Qiagen). RNA samples were converted to cDNA (Life Technologies) and quantified by qPCR 
(Power SYBR Master Mix, Life Technologies; Applied Biosystems Step One Plus instrument). A minus 
RT control was included to control for contaminating genomic DNA. Primer sequences for qPCR were: 
GAPDH_F: 5′-AGCCA CATCG CTCAG ACAC-3′, GAPDH_R: 5′-GCCCA ATACG ACCAA ATCC-
3′, RLUC_F: 5′-CAGTG GTGGG CCAGA TGTAA ACAA-3′, RLUC_R: 5′-TAAGA AGAGG CCGCG 
TTACC ATGT-3′.
Cell transfections. Transient transfections of PH5CH8, LH86, or HeLa cells were performed 
using the pcDNA5/FRT/TO reporter plasmids described above. Cells were plated onto 24-well plates 
at a density of 7.5 × 105 cells/well 24 hours prior to co-transfection with 50ng (LH86, HeLa) or 100ng 
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(PH5CH8) of RLuc reporter plasmids and 20 ng of pGL3 firefly luciferase plasmid (Promega) using 0.5 
μ l Lipofectamine 2000 (Life Technologies). Cells were lysed 24 hours after transfection and luciferase 
measurements were made using by dual luciferase assay (Promega). All reporter plasmids were analyzed 
in triplicate and P values were calculated by unpaired t-test.
A549 transfections for RT-PCR analysis of IFNL3 expression were performed with 7.5 × 105 cells 
plated 24 hours prior to transfection into 24-well plates. Cells were transfected with 800 ng pcDNA5/
FRT/TO plasmid, poly I:C (Sigma), or purified HCV JFH1 strain60 RNA produced by in vitro transcrip-
tion with T7 RNA polymerase (Ambion). Four hours after transfection, total RNA samples were gener-
ated using Trizol reagent (Life Technologies) and used for standard RT-PCR detection of IFNL3 mRNA 
using primers designed to amplify the open reading frame.
Polysome profiling. HeLa cell lines were cultured on 10 cm dishes and processed essentially as 
described61. Briefly, cells were washed, scraped and pelleted in ice-cold PBS containing 200 μ M cyclohex-
imide. Cell pellets were resuspended in 0.4 ml lysis buffer [400 mM KOAc, 25 mM K-HEPES (pH 7.5), 
15 mM Mg(OAc)2, 1 mM DTT, 200 μ M cycloheximide] and incubated on ice for 30 minutes before cen-
trifugation for 10 minutes at 12,000 × g to remove insoluble material. Supernatants were layered onto 
10 ml 15–50% sucrose density gradients containing 400 mM KOAc, 25 mM K-HEPES (pH 7.5) and 
15 mM Mg(OAc)2 and then centrifuged for 3 hours at 35,000 rpm using an SW41 rotor. Gradients were 
fractionated (Isco) and 12 fractions were collected for RNA extraction using Trizol LS (Life Technologies). 
Polysome analysis was conducted with single replicate per cell line in three biological replicates con-
ducted on different days.
RNA SHAPE analysis. Adherent A549 cells were plated in a 6-well culture dish and grown overnight 
to 90% confluency. IFNL3 mRNA was induced by transfecting cells (using Lipofectamine 2000) with 4 
μ g of poly I:C (Sigma) and incubated for 4 hours before washing with PBS (pH 7.2).
For SHAPE modification of total deproteinized mRNA, RNA was purified using a modified Trizol 
(Invitrogen) extraction protocol. The cells were lysed with 1.0 mL of Trizol for 5 min at room temper-
ature. The cell lysate was placed in a microfuge tube and 0.2 mL of chloroform was added followed 
15 seconds of shaking vigorously by hand. The sample was incubated for 2 min at room temperature, 
and the sample was spun in the centrifuge at 12,000 × g for 15 min. The deproteinized total RNA in the 
aqueous layer was removed and immediately equilibrated into native folding buffer [50 mM HEPES (pH 
8.0), 5 mM MgCl2, 200 mM potassium acetate] using a pre-equilibrated G-25 spin column (GE Health 
sciences). Deproteinized RNAs were incubated at 37 oC for 15 minutes in native folding buffer in order 
to allow folding state to come to equilibrium and then treated with 0.1 volume of DMSO, or 100 mM 
1-methyl-7-nitroisatoic anhydride (1M7) in DMSO at 37 oC for 5 min. EDTA was added to 10 mM final 
concentration; reactions were chilled on ice; and the RNA was precipitated with isopropanol. For the 
parallel denaturing modification control, deproteinized total RNA was equilibrated into 1X denaturing 
buffer [50 mM HEPES (pH 8), 4 mM EDTA, 50% formamide] using a pre-equilibrated G-25 spin column; 
heated to 95 oC for 1 min; modified with 0.1 volume of 100 mM 1M7 in DMSO; chilled on ice for 2 min; 
and recovered by precipitation with isopropanol.
SHAPE-MaP library construction. DNA libraries for massively parallel sequencing were prepared 
as described62. Briefly, targeted SHAPE-MaP reverse transcription reactions (20 μ L) contained 2 μ M of 
IFNL3 RT primer (5′-GTCTT TTCCT CATTG TTTAT TTC-3′ ) in 1× SHAPE-MaP buffer [50 mM 
Tris-HCl (pH 8), 75 mM KCl, 6 mM MnCl2] with 1 μ L reverse transcriptase (Superscript II, Invitrogen). 
Reactions were incubated at 42 °C for 3 hours, and cDNA products were purified (G-25 microspin col-
umn; GE Lifesciences). Purified cDNAs were amplified for 20 cycles using Q5 DNA Polymerase (NEB) 
with Illumina adapted IFNL3 targeted primers (Forward 5′-GACTG GAGTT CAGAC GTGTG CTCTT 
CCGAT CNNNN NCCTC CACCA TTGGC TGC-3′, Reverse: 5′-CCCTA CACGA CGCTC TTCCG 
ATCTN NNNNN NNCTC ATTGT TTATT TCAAC AAGGA TTTC-3′ ). The forward primer was 
designed with a 3′ mismatch to the IFNL2 mRNA to limit amplification of this similar transcript. PCR 
primers were designed to amplify sequences spanning different exons, so analyzed PCR product could 
only be generated from a spliced mRNA and not contaminating genomic DNA. PCR products were 
purified using a PureLink PCR purification kit (Invitrogen), and libraries were amplified by a second 
PCR reaction using Q5 DNA Polymerase (NEB) and Illumina TRUseq PCR primers. PCR libraries were 
quantified by fluorescence (Qubit fluorometer; Life Technologies), analyzed with a Bioanalyzer DNA kit 
(Agilent), and sequenced on a MiSeq instrument (Illumina).
SHAPE-MaP data analysis. SHAPE-MaP reactivities for each nucleotide within the IFNL3 3′ UTR 
were generated from the raw FASTQ files. Raw SHAPE reactivity data are shown in Table S1. A custom 
analysis pipeline identified all of the sequencing reads from IFNL3 rs4803217 G, IFNL3 rs4803217 T, and 
IFNL2 mRNAs. IFNL2 reads were determined by analyzing six nucleotide positions that vary between 
IFNL2 and IFNL3. Reads with three or more nucleotide matches to IFNL2 (1.2% of total reads) were 
removed prior to RNA structure analysis. Reads from the two IFNL3 alleles were sorted into separate 
FASTQ files and then analyzed using ShapeMapper62. Shannon entropies and minimum-free energy 
genome secondary structure models were generated from SHAPE reactivities using a custom RNA 
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folding pipeline62. Shannon entropy values were calculated to quantify the well-determinedness of struc-
tural states for a given RNA region. The pipeline interfaces with RNAstructure v5.5 in order to compu-
tationally model RNA secondary structure. The RNA secondary structure models were diagramed using 
VARNA63.
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